Gilead\'s PrEP drug Descovy should be approved for men and transgender women but not cisgender women FDA advisory panel says

Gilead's PrEP drug Descovy should be approved for men and transgender women but not cis-gender women, FDA advisory panel says

05:10 EDT 8 Aug 2019 | Pharmafile

Independent experts on a panel advising the FDA have voted in favour of Gilead’s new PrEP drug Descovy in men and transgender women who have sex with men.

However the panel voted against expanding Descovy’s label to cover the drug as a preventative treatment for cis-gendered women.

Descovy which is a combination of emtricitabine and tenofovir alafenamide, is currently approved as a treatment for chronic HIV.

California drugmaker Gilead are now seeking approval for the drug as a means of reducing the risk of contracting of HIV.

Gilead\'s PrEP drug Descovy should be approved for men and transgender women but not cisgender women FDA advisory panel says

Gilead's PrEP drug Descovy should be approved for men and transgender women but not cis-gender women, FDA advisory panel says

More From BioPortfolio on "Gilead's PrEP drug Descovy should be approved for men and transgender women but not cis-gender women, FDA advisory panel says"